JP2015511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511632A5
JP2015511632A5 JP2015502543A JP2015502543A JP2015511632A5 JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5 JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5
Authority
JP
Japan
Prior art keywords
melanoma
trifluoromethyl
amino
treatment
raf inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/052556 external-priority patent/WO2013144923A1/en
Publication of JP2015511632A publication Critical patent/JP2015511632A/ja
Publication of JP2015511632A5 publication Critical patent/JP2015511632A5/ja
Pending legal-status Critical Current

Links

JP2015502543A 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 Pending JP2015511632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618006P 2012-03-30 2012-03-30
US61/618,006 2012-03-30
PCT/IB2013/052556 WO2013144923A1 (en) 2012-03-30 2013-03-29 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Publications (2)

Publication Number Publication Date
JP2015511632A JP2015511632A (ja) 2015-04-20
JP2015511632A5 true JP2015511632A5 (cg-RX-API-DMAC10.html) 2016-06-02

Family

ID=48326371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502543A Pending JP2015511632A (ja) 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与

Country Status (6)

Country Link
US (1) US20150126533A1 (cg-RX-API-DMAC10.html)
EP (1) EP2830664A1 (cg-RX-API-DMAC10.html)
JP (1) JP2015511632A (cg-RX-API-DMAC10.html)
CN (1) CN104428001A (cg-RX-API-DMAC10.html)
CA (1) CA2868954A1 (cg-RX-API-DMAC10.html)
WO (1) WO2013144923A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
US20190117652A1 (en) * 2014-12-23 2019-04-25 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
EP4065122A4 (en) * 2019-11-27 2023-12-27 Day One Biopharmaceuticals, Inc. SOLID DISPERSION OF PAN-RAF KINASE INHIBITOR
CN117042772A (zh) * 2020-11-06 2023-11-10 首日生物制药公司 用于治疗低级别胶质瘤的raf抑制剂
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合
CA3211167A1 (en) * 2021-02-19 2022-08-25 Samuel C. BLACKMAN Combination of raf inhibitor and mek inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
JP2012502885A5 (cg-RX-API-DMAC10.html)
JP2012530705A5 (cg-RX-API-DMAC10.html)
NO2017023I1 (no) Venetoklaks, dvs. 4-(4-{[2-(4-klorfenyl)-4,4-dimetylsykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-({3-nitro-4[{tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
JP2012517962A5 (cg-RX-API-DMAC10.html)
ME02696B (me) MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI
JP2014524362A5 (cg-RX-API-DMAC10.html)
CN109843893A (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
JP2014062126A5 (cg-RX-API-DMAC10.html)
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
PT2684877T (pt) Sal farmaceuticamente aceitável de (e)-n-[4-[[3-cloro-4-(2- piridilmetoxi)fenil]amino]-3-ciano-7-etoxi-6-quinolil]-3-[(2r)-1-metilpirrolidin-2-il]prop-2-enamida, seu método de preparação e a sua utilização clínica
LT3544976T (lt) N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
BRPI0809655B8 (pt) uso de um composto e um agente terapêutico,composição farmacêutica,e,kit
CN109563082A (zh) 核磁共振显像化合物、其中间体、核磁共振显像剂及应用、以及核磁共振成像方法
JP2016020375A5 (cg-RX-API-DMAC10.html)
PL3544977T3 (pl) Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
JP2012528824A5 (cg-RX-API-DMAC10.html)
IL248772B (en) 2-(5,3-bis(trifluoromethyl)phenyl)-n-6-cyclohexyl-4-(ortho-tolyl)pyridin-3-yl)-n-methylacetamide derivatives and their uses for preventing nausea and vomiting caused by chemotherapy for cancer treatment
EP3643708C0 (en) 2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPH, ITS PREPARATION PROCESS AND APPLICATION
JP2015509917A5 (cg-RX-API-DMAC10.html)
AU2023903757A0 (en) Use of 2-(3-fluoro-4-(trifluoromethyl)phenyl)-N-(2-(1-hydroxypropan-2-yl)-6-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)acetamide in the treatment of cardiovascular diseases
CN302545738S (zh) 档案包（健康档案）
CN302299186S (zh) 声音重放设备